v3.25.1
Condensed Consolidated Statements of Changes in Equity (Statement) - USD ($)
$ in Thousands
Total
Common Units
Common Stock
Additional Paid-in Capital
Accumulated Other Comprehensive Income
Retained Earnings
Non-controlling Interests
Redeemable noncontrolling interests, beginning balance at Dec. 31, 2023 $ 7,302            
Increase (Decrease) in Temporary Equity [Roll Forward]              
Net loss attributable to redeemable noncontrolling interests (2,285)            
Redeemable noncontrolling interests, ending balance at Mar. 31, 2024 5,017            
Common units balance, beginning of period (in shares) at Dec. 31, 2023 [1]   484,922,828          
Balance, beginning of period at Dec. 31, 2023 1,075,014 $ 496,882     $ 18,561 $ 155,453 $ 404,118
Increase (Decrease) in Stockholders' Equity [Roll Forward]              
Net income attributable to Ardent Health Partners, Inc. 27,047         27,047  
Net income attributable to noncontrolling interests 21,089           21,089
Other comprehensive income (loss) 703       703    
Distributions to noncontrolling interests (14,256)           (14,256)
Vesting of Class C Units (in shares) [1]   464,853          
Issuance of stock 512 $ 512          
Common units balance, ending of period (in shares) at Mar. 31, 2024 [1]   485,387,681          
Balance, ending of period at Mar. 31, 2024 1,110,109 $ 497,394     19,264 182,500 410,951
Redeemable noncontrolling interests, beginning balance at Dec. 31, 2024 1,158            
Increase (Decrease) in Temporary Equity [Roll Forward]              
Net loss attributable to redeemable noncontrolling interests (1,350)            
Redeemable noncontrolling interests, ending balance at Mar. 31, 2025 (192)            
Balance, beginning of period at Dec. 31, 2024 $ 1,521,199 [2]   $ 1,428 $ 754,415 9,737 365,796 389,823
Balance, beginning of period (in shares) at Dec. 31, 2024 142,747,818   142,747,818        
Increase (Decrease) in Stockholders' Equity [Roll Forward]              
Net income attributable to Ardent Health Partners, Inc. $ 41,383         41,383  
Net income attributable to noncontrolling interests 18,932           18,932
Other comprehensive income (loss) (5,809)       (5,809)    
Distributions to noncontrolling interests (19,239)           (19,239)
Vesting of restricted stock unit awards (in shares)     289,946        
Equity-based compensation 9,263     9,263      
Balance, ending of period at Mar. 31, 2025 $ 1,564,668 [2]   $ 1,430 762,615 $ 3,928 $ 407,179 $ 389,516
Balance, ending of period (in shares) at Mar. 31, 2025 143,037,764   143,037,764        
Increase (Decrease) in Stockholders' Equity [Roll Forward]              
Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures $ (1,061)   $ 2 $ (1,063)      
[1] (*) See Note 1, Description of the Business and Basis of Presentation - Initial Public Offering and Corporate Conversion, for further discussion.
[2] As of March 31, 2025 and December 31, 2024, the unaudited condensed consolidated balance sheets included total liabilities of consolidated variable interest entities of
$304.8 million and $306.4 million, respectively. Refer to Note 2, Summary of Significant Accounting Policies, for further discussion.